FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360868820> ?p ?o ?g. }

• W4360868820 abstract "Background: The United States (US) ranks high, nationally, in opioid consumption. The ongoing increase in the misuse and mortality amid the opioid epidemic has been contributing to its rising cost. The worsening health and economic impact of opioid use disorder in the US warrants further attention. We, therefore, assessed commonly prescribed opioids to determine the opioids that were over-represented versus under-represented for adverse drug events (ADEs) to better understand their distribution patterns using the Food and Drug Administration’s Adverse Event Reporting System (FAERS) while correcting for distribution using the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS). Comparing the ratio of the percentage of adverse drug events as reported by the FAERS relative to the percentage of distribution as reported by the ARCOS database is a novel approach to evaluate post-marketing safety surveillance and may inform healthcare policies and providers to better regulate the use of these opioids. Methods: We analyzed the adverse events for 11 prescription opioids, when correcting for distribution, and their ratios for three periods, 2006–2010, 2011–2016, and 2017–2021, in the US. The opioids include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol. Oral morphine milligram equivalents (MMEs) were calculated by conversions relative to morphine. The relative ADEs of the selected opioids, opioid distributions, and ADEs relative to distribution ratios were analyzed for the 11 opioids. Results: Oxycodone, fentanyl, and morphine accounted for over half of the total number of ADEs ( n = 667,969), while meperidine accounted for less than 1%. Opioid distributions were relatively constant over time, with methadone repeatedly accounting for the largest proportions. Many ADE-to-opioid distribution ratios increased over time, with meperidine (60.6), oxymorphone (11.1), tapentadol (10.3), and hydromorphone (7.9) being the most over-represented for ADEs in the most recent period. Methadone was under-represented (&lt;0.20) in all the three periods. Conclusion: The use of the FAERS with the ARCOS provides insights into dynamic changes in ADEs of the selected opioids in the US. There is further need to monitor and address the ADEs of these drugs." @default.
• W4360868820 created "2023-03-25" @default.
• W4360868820 creator A5000782341 @default.
• W4360868820 creator A5031884954 @default.
• W4360868820 creator A5068788366 @default.
• W4360868820 date "2023-03-24" @default.
• W4360868820 modified "2023-09-25" @default.
• W4360868820 title "Variation in adverse drug events of opioids in the United States" @default.
• W4360868820 cites W1610991453 @default.
• W4360868820 cites W1970401253 @default.
• W4360868820 cites W1978507976 @default.
• W4360868820 cites W2016433803 @default.
• W4360868820 cites W2018528388 @default.
• W4360868820 cites W2024238924 @default.
• W4360868820 cites W2027710934 @default.
• W4360868820 cites W2028419780 @default.
• W4360868820 cites W2028952268 @default.
• W4360868820 cites W2113514677 @default.
• W4360868820 cites W2131298256 @default.
• W4360868820 cites W2132974770 @default.
• W4360868820 cites W2140359307 @default.
• W4360868820 cites W2156733880 @default.
• W4360868820 cites W2161976818 @default.
• W4360868820 cites W2215821313 @default.
• W4360868820 cites W2592031711 @default.
• W4360868820 cites W2680859276 @default.
• W4360868820 cites W2725503094 @default.
• W4360868820 cites W2793837493 @default.
• W4360868820 cites W2903520456 @default.
• W4360868820 cites W2908836410 @default.
• W4360868820 cites W2912278512 @default.
• W4360868820 cites W2945784922 @default.
• W4360868820 cites W2968821050 @default.
• W4360868820 cites W2972040154 @default.
• W4360868820 cites W2974591383 @default.
• W4360868820 cites W2988612943 @default.
• W4360868820 cites W2991029508 @default.
• W4360868820 cites W3010667056 @default.
• W4360868820 cites W3037281766 @default.
• W4360868820 cites W3092922344 @default.
• W4360868820 cites W3095492073 @default.
• W4360868820 cites W3109548321 @default.
• W4360868820 cites W3109878602 @default.
• W4360868820 cites W3131873437 @default.
• W4360868820 cites W3138734623 @default.
• W4360868820 cites W3158872618 @default.
• W4360868820 cites W3161131015 @default.
• W4360868820 cites W3168192969 @default.
• W4360868820 cites W3169023464 @default.
• W4360868820 cites W3176705879 @default.
• W4360868820 cites W3199681174 @default.
• W4360868820 cites W3205115907 @default.
• W4360868820 cites W4238440976 @default.
• W4360868820 cites W4295106475 @default.
• W4360868820 cites W4309660462 @default.
• W4360868820 cites W4318562100 @default.
• W4360868820 doi "https://doi.org/10.3389/fphar.2023.1163976" @default.
• W4360868820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37033633" @default.
• W4360868820 hasPublicationYear "2023" @default.
• W4360868820 type Work @default.
• W4360868820 citedByCount "1" @default.
• W4360868820 countsByYear W43608688202023 @default.
• W4360868820 crossrefType "journal-article" @default.
• W4360868820 hasAuthorship W4360868820A5000782341 @default.
• W4360868820 hasAuthorship W4360868820A5031884954 @default.
• W4360868820 hasAuthorship W4360868820A5068788366 @default.
• W4360868820 hasBestOaLocation W43608688201 @default.
• W4360868820 hasConcept C126322002 @default.
• W4360868820 hasConcept C170493617 @default.
• W4360868820 hasConcept C194828623 @default.
• W4360868820 hasConcept C197934379 @default.
• W4360868820 hasConcept C2776029756 @default.
• W4360868820 hasConcept C2776316548 @default.
• W4360868820 hasConcept C2776389719 @default.
• W4360868820 hasConcept C2777105317 @default.
• W4360868820 hasConcept C2777389121 @default.
• W4360868820 hasConcept C2777866328 @default.
• W4360868820 hasConcept C2778767360 @default.
• W4360868820 hasConcept C2778949969 @default.
• W4360868820 hasConcept C2779158186 @default.
• W4360868820 hasConcept C2780505013 @default.
• W4360868820 hasConcept C2781063702 @default.
• W4360868820 hasConcept C2781072394 @default.
• W4360868820 hasConcept C42219234 @default.
• W4360868820 hasConcept C71924100 @default.
• W4360868820 hasConcept C98274493 @default.
• W4360868820 hasConceptScore W4360868820C126322002 @default.
• W4360868820 hasConceptScore W4360868820C170493617 @default.
• W4360868820 hasConceptScore W4360868820C194828623 @default.
• W4360868820 hasConceptScore W4360868820C197934379 @default.
• W4360868820 hasConceptScore W4360868820C2776029756 @default.
• W4360868820 hasConceptScore W4360868820C2776316548 @default.
• W4360868820 hasConceptScore W4360868820C2776389719 @default.
• W4360868820 hasConceptScore W4360868820C2777105317 @default.
• W4360868820 hasConceptScore W4360868820C2777389121 @default.
• W4360868820 hasConceptScore W4360868820C2777866328 @default.
• W4360868820 hasConceptScore W4360868820C2778767360 @default.
• W4360868820 hasConceptScore W4360868820C2778949969 @default.
• W4360868820 hasConceptScore W4360868820C2779158186 @default.
• W4360868820 hasConceptScore W4360868820C2780505013 @default.

• next